Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportMolecular Targeting Probes-Radioactive & Nonradioactive - Preclinical Probes for Oncology

PEGylation: an effective therapeutic radiopharmaceutical development strategy

Jieting Shen, Siqi Zhang, Jiang Wu, Jing Xu, Xingkai Wang, Lulu Zhang, Lin Xie, Rui Wang, Ming-Rong Zhang and Kuan Hu
Journal of Nuclear Medicine June 2024, 65 (supplement 2) 241836;
Jieting Shen
1State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Siqi Zhang
1State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jiang Wu
2Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jing Xu
1State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xingkai Wang
1State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lulu Zhang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lin Xie
3Department of Advanced Nuclear Medicine Sciences, Institute for Quantum Medical Science, National Institutes for Quantum and Radiological Science and Technology
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rui Wang
4Chinese Academy of Medical Sciences
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ming-Rong Zhang
5National Institutes for Quantum and Radiological Science and Technology
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kuan Hu
1State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Abstract

241836

Introduction: Polyethylene glycol (PEG) is a widely used drug modification polymer with low toxicity and low immunogenicity. PEGylation is an effective strategy to alter pharmacokinetic properties, including an enhanced solubility, an improved stability, a reduced renal clearance, and a prolonged circulation halflife in biological fluids, which dramatically improves pharmaceutical value.

Many factors contribute to the effect of PEG on peptide molecules, including the size, the number and the topological structure of attached PEG molecules, and the conjugation position of PEG moieties. To explore how topology and polyvalency, of PEGylation, influence the in vivo fate of peptides, we labeled PD-L1 targeting TPP-1 peptide with PEG molecules with different topological structures. By leveraging with 64Cu-PET, we revealed the "topological effects" of PEG molecules in modulating the in vivo pharmacokinetics and their theranostics potential in mouse models.

Methods: Based on the PD-L1-targeted TPP-1 peptide, a monomeric precursor, NOTA-TPP, was generated by conjugation of bifunctional chelator NOTA. Then, we designed and synthesized a series of PEGylated peptide multimers, , NOTA-TPP-(4)PEG, and NOTA-TPP-(8)PEG. Radiolabeled with 64Cu, they were evaluated in in vitro and in vivo studies to compare differences in radiochemical and therapeutic abilities. The radiochemical yield (RCY) and molar activity were analyzed by radio HPLC. The stability in mouse serum was evaluated. Therapeutic study was carried out in MC38 tumor-bearing mice models (n=5) (Figure A). After intravenous injection of approximately 37 MBq radioconjugate per mouse, tumor volume, body weight and survival of mouse were recorded on days 6, 9, 12, 15, 19, 21, 23 and 25 post treatment.

Results: Monitored by radio-HPLC, the RCY of [64Cu]NOTA-TPP and [64Cu]NOTA-TPP-(1)PEG were >98%, while that of [64Cu]NOTA-TPP-(4)PEG and [64Cu]NOTA-TPP-(8)PEG was >78.2%. The molar activity of [64Cu]NOTA-TPP-(1)PEG, [64Cu]NOTA-TPP-(4)PEG and [64Cu]NOTA-TPP-(8)PEG were more than 37 GBq/μmol, while the molar activity of was more than 74 GBq/μmol. The half-life also changed among different arm number of PEG. The half-life of [64Cu]NOTA-TPP-(1)PEG, [64Cu]NOTA-TPP-(4)PEG and [64Cu]NOTA-TPP-(8)PEG were more than 12 hours, while the half-life of [64Cu]NOTA-TPP was only about 80 min.

In the therapeutic study, mice in [64Cu]NOTA-TPP group had the most rapid tumor growth and more than 50% tumor-bearing mice were euthanized by day 23 because of excessive tumor volume. In [64Cu]NOTA-TPP-(1)PEG and [64Cu]NOTA-TPP-(4)PEG group, tumor volume reached 786.28±504.72 mm3 and 753.58±552.22 mm3 at day 21 post injection, respectively, and less than 50% mice were euthanized. In [64Cu]NOTA-TPP-(8)PEG group, tumor volume increased insignificantly and kept at a small level of 198.27±237.59 mm3 at day 21 post injection, and all mice survived until the end of the experiment. The normalized average body weight in all therapeutic groups increased slightly.

Conclusions: Through this proof-of-principle study, PEGylation proves to be an effective strategy to improve the stability of peptide precursors. Multimerization via PEGylation significantly improved tumor affinity and retention in blood, and expanded its application in tumor therapy. Moreover, the radiolabeled multimer [64Cu]NOTA-TPP-(8)PEG is found an promising radiotheranostic agent for PD-L1 PET imaging and imaging-guided treatment.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 65, Issue supplement 2
June 1, 2024
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
PEGylation: an effective therapeutic radiopharmaceutical development strategy
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
PEGylation: an effective therapeutic radiopharmaceutical development strategy
Jieting Shen, Siqi Zhang, Jiang Wu, Jing Xu, Xingkai Wang, Lulu Zhang, Lin Xie, Rui Wang, Ming-Rong Zhang, Kuan Hu
Journal of Nuclear Medicine Jun 2024, 65 (supplement 2) 241836;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
PEGylation: an effective therapeutic radiopharmaceutical development strategy
Jieting Shen, Siqi Zhang, Jiang Wu, Jing Xu, Xingkai Wang, Lulu Zhang, Lin Xie, Rui Wang, Ming-Rong Zhang, Kuan Hu
Journal of Nuclear Medicine Jun 2024, 65 (supplement 2) 241836;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Molecular Targeting Probes-Radioactive & Nonradioactive - Preclinical Probes for Oncology

  • Development of a novel TKI-PET probe targeting EGFR mutation
  • PD-L1 imaging and T cell imaging jointly achieve precise combination therapy of radiotherapy and immunotherapy
  • Optimizing Fc-engineered novel anti-MSLN VH-Fc fusion proteins through PET imaging
Show more Molecular Targeting Probes-Radioactive & Nonradioactive - Preclinical Probes for Oncology

PEGylation: an effective therapeutic radiopharmaceutical development strategy

  • Development of a novel TKI-PET probe targeting EGFR mutation
  • PD-L1 imaging and T cell imaging jointly achieve precise combination therapy of radiotherapy and immunotherapy
  • Optimizing Fc-engineered novel anti-MSLN VH-Fc fusion proteins through PET imaging
Show more PEGylation: an effective therapeutic radiopharmaceutical development strategy

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire